1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,650 | 6,050 | 21:16 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.03. | WUXI XDC (02268): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ALL ... | 8 | HKEx | ||
| 02.03. | M Stanley: WUXI XDC 's Shr Price to Rise Absolutely in Next 30 Days | 1 | AASTOCKS | ||
| 27.02. | WuXi XDC, Earendil Labs Partner to Accelerate the Development of ADCs | 1 | Contract Pharma | ||
| 27.02. | Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs | 2 | FierceBiotech | ||
| 27.02. | WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform | 315 | PR Newswire | SHANGHAI, Feb. 27, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization)... ► Artikel lesen | |
| WUXI XDC Aktie jetzt für 0€ handeln | |||||
| 27.02. | CLSA: Decline in WUXI BIO/WUXI XDC on Thu Not Driven by Fundamentals | 8 | AASTOCKS | ||
| 20.02. | M Stanley Cuts TP for WUXI XDC to HKD86, Rating Overweight | 1 | AASTOCKS | ||
| 11.02. | WUXI XDC (02268): MAJOR TRANSACTION IN RELATION TO VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE ... | - | HKEx | ||
| 11.02. | WUXI XDC (02268): JOINT ANNOUNCEMENT DESPATCH OF COMPOSITE DOCUMENT RELATING TO VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED ... | 1 | HKEx | ||
| 11.02. | WUXI XDC (02268): PINK FORM OF OPTION OFFER ACCEPTANCE AND CANCELLATION OF SHARE OPTIONS GRANTED BY BIODLINK INTERNATIONAL COMPANY LIMITED | 1 | HKEx | ||
| 11.02. | WUXI XDC (02268): WHITE FORM OF SHARE OFFER ACCEPTANCE AND TRANSFER OF ORDINARY SHARE(S) IN THE ISSUED SHARE CAPITAL OF BIODLINK INTERNATIONAL COMPANY ... | 3 | HKEx | ||
| 11.02. | WUXI XDC (02268): COMPOSITE OFFER AND RESPONSE DOCUMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF ... | 1 | HKEx | ||
| 04.02. | WUXI XDC (02268): DELAY IN DESPATCH OF CIRCULAR | - | HKEx | ||
| 04.02. | WUXI XDC (02268): JOINT ANNOUNCEMENT DELAY IN DESPATCH OF COMPOSITE DOCUMENT RELATING TO VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ... | 4 | HKEx | ||
| 23.01. | WUXI XDC (02268): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 22.01. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 15.01. | EQS Newswire: Gelonghui: WuXi XDC issues positive profit alert, to acquire BioDlink in bid to strengthen ADC CDMO lead | 576 | EQS Group (EN) | EQS Newswire / 15/01/2026 / 12:50 UTC+8
January 14, 2026 - WuXi XDC has issued a positive profit alert for fiscal 2025 and announced a cash tender offer for BioDlink, whose shares were suspended... ► Artikel lesen | |
| 14.01. | WUXI XDC (02268): INSIDE INFORMATION PRESENTATION AT 2026 ANNUAL HEALTHCARE CONFERENCE | - | HKEx | ||
| 14.01. | WUXI XDC (02268): JOINT ANNOUNCEMENT (1) VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ... | 1 | HKEx | ||
| 14.01. | WUXI XDC (02268): POSITIVE PROFIT ALERT | 1 | HKEx |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 34,805 | -1,28 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen bei unverändertem Kursziel von 54 US-Dollar von "Hold" auf "Buy" hochgestuft. Analyst Jan Koch kehrt nach seiner Abstufung im Januar... ► Artikel lesen | |
| EVOTEC | 4,297 | -0,30 % | Hausse oder Baisse? Nicht alles was glänzt ist Gold! Evotec, TeamViewer und Lahontan Gold zum Rapport | Bei Volatilität in diesem Ausmaß suchen Investoren nach stabilen Aktien. Gar nicht so leicht, denn an Tagen, wenn der Ölpreis mit 35 USD Aufschlag in den Morgen startet werden Aktien auch mal panisch... ► Artikel lesen | |
| TANGO THERAPEUTICS | 19,405 | +0,49 % | Tango Therapeutics' (TNGX) Sees Cautious Analyst Optimism Following Earnings | ||
| DAY ONE BIOPHARMACEUTICALS | 21,390 | -0,02 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| ARCELLX | 114,80 | +0,40 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| BIONTECH | 77,50 | +0,26 % | BioNTech-Aktie: Vielen Dank, und tschüss! | Die Nachricht über den Gründer-Rückzug bei BioNTech löste zunächst einen regelrechten Ausverkauf aus. Die Aktie des deutschen mRNA-Spezialisten brach im Tief um rund 25% ein. Die folgende kurzfristige... ► Artikel lesen | |
| ERASCA | 14,600 | -4,32 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| ARS PHARMACEUTICALS | 8,170 | -0,85 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization | neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 297,56 | +0,02 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 66,16 | -3,43 % | Truist initiates Apogee Therapeutics stock with Hold on high bar | ||
| CG ONCOLOGY | 65,06 | -1,26 % | CG Oncology stock rating reiterated at Buy by Truist Securities | ||
| MONTE ROSA THERAPEUTICS | 15,630 | -2,62 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,325 | -4,69 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| COGENT BIOSCIENCES | 33,420 | -3,41 % | Cogent Biosciences Stock Climbs After FDA Accepts Key Drug Application | ||
| DYNE THERAPEUTICS | 17,570 | -1,21 % | Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs |
WUXI XDC CAYMAN INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 5,750 Euro und damit -2,54 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WUXI XDC CAYMAN INC finden Sie auf Wallstreet Online.